Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
BUSINESS
Opdivo Ranks 2nd in FY2016 Japan Sales Ranking after Harvoni: QuintilesIMS
Ono Pharmaceutical’s immuno-oncology med Opdivo (nivolumab) raked in sales of nearly 119 billion yen on an NHI price basis in FY2016 (April 2016-March 2017), jumping about six-fold year on year to clinch the No. 2 spot in Japan’s drug sales…
To read the full story
Related Article
BUSINESS
- Kissei Begins Briefing Healthcare Providers on Tavneos Data Concerns
October 22, 2026
- Foreign Pharma Sales in Japan Seen Rising 7.7% in 2026: Fuji Keizai
October 22, 2026
- Shionogi’s Olorofim Tops AmBisome in Day 84 Response Rate in Global PIII
October 22, 2026
- RaQualia to Receive 200 Million Yen from Hisamitsu as Pain Patch Enters PII
October 22, 2026
- Healios Eyes 2028 Launch of Kobe Cell Manufacturing Facility
October 22, 2026
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…